Document:

Exhibit 10.56

 

AMENDMENT NO. 6

TO

ACTINIUM PHARMACEUTICALS, INC. 2013 AMENDED AND RESTATED STOCK PLAN

 

Pursuant to Section 14 of the 2013 Amended and Restated Stock
Plan, as amended (the “Plan”) of Actinium Pharmaceuticals, Inc. (the “Company”), the Board of Directors
of the Company has duly adopted a resolution, conditioned upon approval by the stockholders of the Company, approving this Amendment
No. 5 to the Plan to increase the total number of shares of common stock, par value $.001 per share, of the Company (the “Common
Stock”) reserved and available for issuance under the Plan as follows:

 

		1.	Section 3 of the Plan is hereby amended to read in its
entirety as follows:

 

“Subject to the provisions of Section 14 of the
Plan, the maximum aggregate number of Shares reserved for issuance to Participants under the Plan is 17,750,000, and the maximum
aggregate number of Shares that may be granted in the form of Incentive Stock Options is 17,750,000. The Shares may be authorized,
but unissued, or reacquired Common Stock. If an award should expire or become unexercisable for any reason without having been
exercised in full, or is surrendered pursuant to an Option Exchange Program, the unpurchased Shares that were subject thereto shall,
unless the Plan shall have been terminated, become available for future grant under the Plan. In addition, any Shares of Common
Stock which are retained by the Company upon exercise of an award in order to satisfy the exercise or purchase price for such award
or any withholding taxes due with respect to such exercise or purchase shall be treated as not issued and shall continue to be
available under the Plan. Shares issued under the Plan and later repurchased by the Company pursuant to any repurchase right which
the Company may have shall not be available for future grant under the Plan.”

 

		2.	All other terms and provisions of the Plan shall remain
unchanged and in full force and effect as written.

 

		3.	A majority in voting interest of the stockholders present
in person or by proxy and entitled to vote at the meeting of stockholders at which this Amendment No. 5 was considered, has duly
approved this Amendment No. 5 to the Plan.

 

IN WITNESS WHEREOF, this Amendment No. 5 to the Plan
is made effective this 14  day of March, 2018.

 

	 	 	ACTINIUM PHARMACEUTICALS, INC.
	 	 	 	 	 
	 	 	By:	 	/s/
Sandesh Seth – Chairman and CEOExhibit 10.57

 

 

October 16, 2017

 

 

Dale Ludwig

21 Fernwood Road

Rockaway, NJ 07866-2028

Dear Mr. Ludwig,

 

On behalf of Actinium
Pharmaceuticals, Inc. (the “Company”), I am pleased to offer you the position of Chief Scientific Officer. This
position serves as a named executive officer of the company. Speaking for myself, as well as the other members of the Company’s
Board of Directors (the “Board”), we are all very impressed with your credentials and look forward to your future
success in this position.

 

1. Position. The terms of your new
position with the Company are as set forth below:

 

(a)       You
shall serve as Chief Scientific Officer.

 

You shall report to the
Chief Executive Officer or appropriate company officer, as designated by the CEO, Board or its representative, and shall perform
your duties for the Company at the Company’s offices in New York City, except for travel that may be necessary or appropriate
in connection with the performance of your duties hereunder. The offices of the Company are currently located in New York City
at 275 Madison Avenue, 7th Floor, New York, NY 10016.

 

(b)       You
agree to devote your best efforts and substantially all of your business time to advance the interests of the Company and to discharge
adequately your duties hereunder.

 

2. Start Date.
Subject to fulfillment of any conditions imposed by this letter agreement, you will commence this new position with the Company
no later than January 2, 2018 (“Start Date”), subject to Board approval prior to the Start Date. The Company
has the right to withdraw this Offer if you are unable to fulfill the Start Date requirement.

 

3. Proof of Right
to Work. For purposes of federal immigration law, you will be required to provide to the Company documentary evidence of your
identity and eligibility for employment in the United States. Such documentation must be provided to us within three (3) business
days of your date of hire, or our employment relationship with you may be terminated.

 

    

     

    

 

4. Compensation.

 

(a)       Base
Salary. You will be paid an annual base salary of Three Hundred Twenty Five Thousand dollars ($325,000), which will be paid in
accordance with the Company's regular payroll practices.

 

(b)       Performance
Bonus. You shall be entitled to participate in an executive bonus program, which shall be established by the Board pursuant to
which the Board may award bonuses of up to 30% to you, based upon the achievement of written individual and corporate objectives
such as the Board shall determine.

 

(c)       Stock
Option Grant. The Board has agreed to grant you an option grant to purchase 200,000 common shares of the Company (the “Grant”)
and is subject to approval by the Compensation Committee.

 

(i) Stock Options.
Such options will have an exercise price equal to the closing price of the Company’s common stock on your first day of employment
(the “Grant Date”).

 

(ii) Vesting Schedule. Twenty-eight percent
(28%) of the initial options or restricted stock granted shall vest twelve months after the date of grant and two percent (2%)
of the remainder shall vest each month thereafter until fully vested. Such additional options or restricted stock will have an
exercise price per share which is equal to fair market value as determined by the Board on the date of the grant. Two percent (2%)
of such additional options or stock shall vest each month thereafter until fully vested. The term of all options granted under
this Agreement will be for 10 years from the date of grant, subject to your continuing service with the Company. The options or
restricted stock will be incentive stock options or stock to the maximum extent allowed by the tax code and will be subject to
the terms of the Company’s Amended and Restated 2014 Stock Plan, as amended, and the Stock Option Agreement between you and
the Company.

 

5. Benefits.

 

a. Benefit plan –
Health Insurance. The Company will provide you with the opportunity to participate in the standard benefits plans currently
available to other similarly situated employees. The Company reserves the right to cancel and/or change the benefits plans it offers
to its employees at any time, subject to applicable law.

 

b. Vacation; Sick
Leave. You will be entitled to 20 days paid vacation per year, pro-rated for the remainder of this calendar year. Vacation
may not be taken before it is accrued. You will be entitled to 5 days paid sick leave per year pro-rated.

 

c. Other Benefits.
The Company will provide you with standard business reimbursements (including mileage, supplies, long distance calls), subject
to Company policies and procedures and with appropriate receipts. In addition, you will receive any other statutory benefits required
by law.

 

    2

     

    

 

d. Reimbursement of
Expenses. You shall be reimbursed for all normal items of travel and entertainment and miscellaneous expenses reasonably incurred
by you on behalf of the Company provided such expenses are documented and submitted in accordance with the reimbursement policies
in effect from time to time.

 

6. Confidential
Information and Invention Assignment Agreement. Your acceptance of this offer and commencement of employment with the Company
is contingent upon the execution, and delivery to an officer of the Company, of the Company’s Confidential Information and
Invention Assignment Agreement, a copy of which is enclosed for your review and execution (the “Confidentiality Agreement”),
prior to or on your Start Date.

 

7. At-Will Employment.
Your employment with the Company will be on an “at will” basis, meaning that either you or the Company may terminate
your employment at any time for any reason or no reason, without further obligation or liability.

 

8. Non-Competition.
During the term and for a period of three (3) years thereafter, you shall not, either directly or indirectly, engage (as principal,
partner, employee, consultant, owner, independent contractor, advisor or otherwise, with or without compensation) in any business
that directly or indirectly competes with the Company (the “Competing Business”). Notwithstanding the foregoing, this
does not prevent you from being engaged or employed with a business that has a Competing Business as part of its business, so long
as you are not engaged or involved in any way in the Competing Business at such business or enterprise.

 

9. Non-Solicitation.
You agree that during the term of your employment with the Company, and for a period of 24 months following the cessation of employment
with the Company for any reason or no reason, you shall not directly or indirectly solicit, induce, recruit or encourage any of
the Company’s employees or consultants to terminate their relationship with the Company, or attempt any of the foregoing,
either for yourself or any other person or entity. For a period of 24 months following cessation of employment with the Company
for any reason or no reason, you shall not attempt to negatively influence any of the Company’s clients or customers from
purchasing Company products or services or to solicit or influence or attempt to influence any client, customer or other person
either directly or indirectly, to direct his or its purchase of products and/or services to any person, firm, corporation, institution
or other entity in competition with the business of the Company.

 

10. Arbitration.
Any dispute or claim arising out of or in connection with your employment with the Company (except with regard to enforcement of
the Confidentiality Agreement) will be finally settled by arbitration in New York, New York in accordance with the Commercial Arbitration
Rules of the American Arbitration Association by one arbitrator appointed in accordance with said rules. Judgment on the award
rendered by the arbitrator may be entered in any court having jurisdiction thereof. The parties agree that this Agreement evidences
a transaction involving interstate commerce and that the operation, interpretation and enforcement of this arbitration provision,
the procedures to be used in conducting an arbitration pursuant to this arbitration provision, and the confirmation of any award
issued to either party by reason of such arbitration, is governed exclusively by the Federal Arbitration Act, 9 U.S.C. § 21
et seq. Notwithstanding the foregoing, the parties may apply to any court of competent jurisdiction for preliminary or interim
equitable relief, or to compel arbitration in accordance with this paragraph, without breach of this arbitration provision.

 

    3

     

    

 

11. Miscellaneous.
This Agreement, together with the Confidentiality Agreement, sets forth the terms of your employment with the Company and supersedes
any prior representations or agreements, whether written or oral. This Agreement may not be modified or amended except by a written
agreement, signed by the Company and by you. Whenever possible, each provision of this Agreement will be interpreted in such manner
as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable
in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will be lessened
or reduced to the extent possible or will be severed and will not affect any other provision and this Agreement will be reformed,
construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein.
This Agreement will be governed by New York law without reference to rules of conflicts of law. All notices, requests, demands
and other communications called for hereunder shall be in writing and shall be deemed given (i) on the date of delivery if delivered
personally, (ii) one (1) day after being sent by a well established commercial overnight service, (iii) three (3) days after being
mailed by registered or certified mail, return receipt requested, prepaid and addressed to the parties or their successors at the
following addresses, or at such other addresses as the parties may later designate in writing, (iv) upon confirmation of facsimile
transfer, if sent by facsimile or (v) upon confirmation of delivery when directed to the electronic mail address set forth below,
if sent by electronic mail:

 

	 	If to the Company:	275 Madison Avenue, Suite 702
	 	 	New York,
NY 10016
	 	 	 
	 	If to you:	Dale L. Ludwig, Ph.D.
	 	 	21 Fernwood Road
	 	 	Rckaway, NJ 07866-2028

 

We are all delighted
to be able to extend you this offer and look forward to working with you. To indicate your acceptance of the Company’s offer,
please sign and date this letter in the space provided below and return it to me, along with a signed and dated copy of the Confidentiality
Agreement.

 

(signature page follows)

 

    4

     

    

 

	Very truly yours, 	 	ACCEPTED AND AGREED:
	 	 	 	 
	ACTINIUM PHARMACEUTICALS, INC.	 	DALE L. LUDWIG

	 	 	 	 
	By: 	/s/ Sandesh Seth	 	/s/
    Dale Ludwig
	 	 	 	Signature
	Name: Sandesh Seth	 	 
	Title: Executive Chairman	 	 

 

 

5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00281-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00281-of-00352.parquet"}]]